1. Home
  2. RXRX vs RAPP Comparison

RXRX vs RAPP Comparison

Compare RXRX & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Recursion Pharmaceuticals Inc.

RXRX

Recursion Pharmaceuticals Inc.

HOLD

Current Price

$3.79

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$38.99

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RXRX
RAPP
Founded
2013
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
RXRX
RAPP
Price
$3.79
$38.99
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$7.50
$48.50
AVG Volume (30 Days)
20.6M
374.3K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
14.79
24.34
EPS
N/A
N/A
Revenue
$74,681,000.00
N/A
Revenue This Year
$12.11
N/A
Revenue Next Year
$82.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.92
N/A
52 Week Low
$2.77
$13.43
52 Week High
$7.18
$43.76

Technical Indicators

Market Signals
Indicator
RXRX
RAPP
Relative Strength Index (RSI) 63.92 52.97
Support Level $2.88 $33.54
Resistance Level $4.01 $40.61
Average True Range (ATR) 0.22 2.47
MACD 0.06 0.13
Stochastic Oscillator 73.18 42.09

Price Performance

Historical Comparison
RXRX
RAPP

About RXRX Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: